Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERIFY-3: Itepekimab in COPD
NCT05326412Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2022
- Primary completion
- Mar 2025
- Countries
- 7
01
Overview
A Phase 2 trial of itepekimab in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started May 2022; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05326412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05326412.